

NatiVita 



INNOVATIONS FOR LIFE

COMPANY PROFILE



- ✚ Launched in 2012
- ✚ International innovative medications research and manufacturing center
- ✚ First to launch production of monoclonal antibody-based biotech drugs in Belarus
- ✚ Investment support from ZIA Valda (Lithuania), Natco Pharma (India), Invest Pharma (Slovakia)

MANUFACTURING SITE

Vitebsk, Belarus



Production of **pharmaceuticals:**



Tablets and capsules



Sterile lyophilized
powders



PRODUCTION LINE

NatiVita⁺

- ✦ State-of-the-art manufacturing complex
- ✦ Full-cycle production in line with **European GMP** (Good Manufacturing Practice) standard
- ✦ Advanced ventilation and air conditioning systems
- ✦ Eco-friendliness, cleanliness and safety



PRODUCTION LINE

Isolator-based manufacturing technology

- 🛡️ Ultra high quality & safety
- 🛡️ Environmental and occupational safety
- 🛡️ Environmental and occupational safety

Quality Control


- 🛡️ Rigorous A-Z production control
- 🛡️ Latest equipment from top-tier manufacturers:



METTLER TOLEDO



memmert



MABPOINT

Development of monoclonal antibody-based medications

Cancers:

- ✚ Lung cancer, breast cancer, colorectal cancer, pancreatic cancer, head and neck cancer, liver cancer, haemoblastoses

Other diseases:

- ✚ Rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, multiple sclerosis

CHEMMOTION

Development of first-in-Belarus chemical generic drugs

Cancers:




- ✚ Multiple myeloma, lung cancer, lymphocytic leukemia and lymphomas, prostate cancer

Other diseases:

- ✚ Respiratory distress syndrome, pulmonary arterial hypertension, growth hormone deficiency, myocardial infarction, multiple sclerosis

R&D: AREAS OF RESEARCH

Development of original drugs

-  Drug development at clinical testing stage – expedited registration of innovative medications
-  Knowledge-intensive preclinical research
-  Full cycle of innovative medication development in cooperation with world leading scientific centers

Small scale chemical synthesis program

-  Preparation of proprietary substances for regeneration of highly efficient modern generic drugs

Personalized medicinal
vaccines in oncology

Therapeutic vaccines
based on peptides

Designs based on CRISPR / CAS9
technology for genome editing

Biotechnological products
based on monoclonal antibodies

The creation of a research center within the framework of the
Pharmaceutical Cluster “Medicine and Pharmaceuticals. Innovative projects”

NATIVITA IN BELARUS



No 1

in the field of **oncology**



No 5

in **hospital segment**



Direct economic effect for the country in 2016
amounted to more than **\$8** million
(which is **4%** of the hospital market)

NATIVITA'S EXPORT STRATEGY: 2020 OUTLOOK



Company and pharmaceutical product registration in **20** countries by **2020**



Annual export - **\$50** million by **2021**

COOPERATION OPPORTUNITIES



EXPORT:

- ✚ Registration of NatiVita's products and their subsequent distribution in the international markets
- ✚ Marketing support for NatiVita products in international markets
- ✚ Exclusive representation of NatiVita's production abroad

FRANCHISING:

- ✚ Participating in creation of pharmaceutical production on the basis of a franchise agreement:
 - Development of technological project in accordance with international standards of GMP and GLP
 - Selection of equipment in line with manufacturing volumes, product characteristics and international requirements for personnel safety
 - Organization and implementation of production technologies transfer and drug quality control
 - Providing own registration dossiers for pharmaceutical products
 - Staff training

CONTRACT MANUFACTURING:

- ✚ Contract manufacturing of full cycle pharmaceutical product production at NatiVita
- ✚ Licensed manufacturing
- ✚ Pharmaceutical product packaging at NatiVita

PRODUCT PORTFOLIO

NatiVita 



PRODUCT PORTFOLIO



No	Product Name	Production Form/Dosage	Name of original product	Indications
1	Abirateron	Tablets 250 mg	ZYTIGA®, Janssen-Cilag	Treatment of metastatic castration-resistant prostate cancer
2	Bendamustin	Powder for the preparation of concentrate for the preparation of a solution for infusions of 100 mg	Ribomustin, Astellas	Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphomas
3	Bortezomib	Lyophilizate powder for the preparation of a solution for infusions of 3.5 mg	Velcade®, Janssen-Cilag	Multiple myeloma. Mantle cell lymphoma in patients who previously received at least 1 line of therapy
4	Gefitinib	Tablets 250 mg	IRESSA®, AstraZeneca	Locally distributed or metastatic non-small cell lung cancer refractory to chemotherapy regimens containing platinum derivatives

PRODUCT PORTFOLIO



No	Product Name	Production Form/Dosage	Name of original product	Indications
5	Zoledronic acid	Lyophilizate powder for the preparation of a solution for infusions of 4 mg	Zometa®, Novartis	Treatment of hypercalcemia caused by a malignant tumor. Treatment of patients with bone metastases in malignant solid tumors and multiple myeloma in combination with standard antitumor therapy
6	Imatinib	Capsules 100 mg	Glivec®, Novartis	Chronic myelogenous leukemia (blast crisis, exacerbation phase and chronic phase) with failure of previous treatment with Interferon alpha
7	Imatinib	Tablets 400 mg	Glivec®, Novartis	Chronic myelogenous leukemia (blast crisis, exacerbation phase and chronic phase) with failure of previous treatment with interferon alpha
8	Lenalidomide	Capsules 5 mg, 10 mg, 15 mg, 25 mg	Revlimid®, Celgene	In combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one line of therapy

PRODUCT PORTFOLIO



No	Product Name	Production Form/Dosage	Name of original product	Indications
9	Letrozole	Tablets 2,5 mg	Femara®, Novartis	Early stages of breast cancer expressing estrogen receptors in postmenopausal women - as adjuvant therapy
10	Rituximab	Concentrate for the preparation of a solution for infusions 10 mg / ml, 10 ml, 30 ml, 50 ml	Mabthera, Hoffmann-La Roche	Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis
11	Bevacizumab	Concentrate for the preparation of a solution for infusions 100 mg, 400 mg	Avastin, Hoffmann-La Roche	Metastatic colorectal cancer, common and / or metastatic renal cell carcinoma, epithelial ovarian cancer, fallopian tube and primary peritoneal cancer
12	Trastuzumab	Lyophilizate powder for the preparation of a solution for infusions of 150 mg, 440 mg	Herceptin, Hoffmann-La Roche	Breast cancer, a common cancer of the stomach

PRODUCT PORTFOLIO

No	Product Name	Production Form/Dosage	Name of original product	Indications
13	Voriconazole	Tablets 200 mg	Vfend®, Pfizer	Severe invasive forms of candidiasis infections
14	Erlotinib	Tablets 100 mg, 150 mg	Tarceva®, Hoffmann-La Roche	Supportive therapy for locally advanced or metastatic non-small cell lung cancer, locally advanced or metastatic non-small cell lung cancer, locally advanced inoperable or metastatic pancreatic cancer as first-line therapy
15	Bosentan	Tablets 62,5 mg, 125 mg	Tracleer®, Actelion	Treatment of pulmonary arterial hypertension (PAH) in order to improve physical activity tolerance and clinical symptoms in patients of II-IV functional class (FC) according to WHO, adults and children over 3 years old



**Innovation for the benefit
of the Nation**

www.nativita.com